| Company Name: |
Leancare Ltd.
|
| Tel: |
+33 962096793 |
| Email: |
enquiry@leancare.co.uk |
| Products Intro: |
|
|
| | Encainide Basic information |
| Product Name: | Encainide | | Synonyms: | Encainide;Encainide [inn:ban];Unii-sy3J0147nb;4-Methoxy-N-(2-(2-(1-Methylpiperidin-2-yl)ethyl)phenyl)benzaMide;Encainide USP/EP/BP | | CAS: | 37612-13-8 | | MF: | C22H28N2O2 | | MW: | 352.475 | | EINECS: | | | Product Categories: | | | Mol File: | 37612-13-8.mol |  |
| | Encainide Chemical Properties |
| | Encainide Usage And Synthesis |
| Description | Encainide is a membrane-active class I c
agent with complex metabolism and clinical
pharmacology , . To date, its effectiveness
has been proved against ventricular arrhythmias. | | Uses | Cardiac depressant (anti-arrhythmic. | | Uses | Clinical use of encainide is primarily associated with the presence of serious ventricular
tachycardia; however, like flecainide, it is also sufficiently effective for atrial arrhythmia
and is used for natural occurrences. | | Definition | ChEBI: Encainide is 4-Methoxy-N-phenylbenzamide in which the hydrogen at the 2 position of the phenyl group is substituted by a 2-(1-methylpiperidin-2-yl)ethyl group. A class Ic antiarrhythmic, the hydrochloride was used for the treatment of severe or life-threatening ventricular arrhythmias, but it was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack and was withdrawn from the market. It has a role as an anti-arrhythmia drug and a sodium channel blocker. It is a member of piperidines and a member of benzamides. | | Brand name | Enkaid
(Bristol Labs). | | World Health Organization (WHO) | The membrane-stabilizing antiarrhythmic agent encainide was
introduced into medicine in the mid-1980's. The decision to delete the indications
for patients with asymptomatic and less severe symptomatic ventricular
arrhythmias was taken on the basis of the results of a trial (CAST study) that
showed a two-fold increase in deaths in post-myocardiac patients taking encainide
compared with the placebo group. (See also WHO comment for flecainide). | | Side effects | Side effects include central nervous system
activity. | | Synthesis | Encainide, 4-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]-benzamide
(18.1.15), is synthesized by acylating 2-(1-methyl-2-piperidylethyl)aniline with 4-
methoxybenzoic acid chloride. The chemical structure of encainide is substantially
different than other local anesthetics and antiarrhythmics. 
|
| | Encainide Preparation Products And Raw materials |
|